| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8925b769d645f9ff06af9f4b189f6a99 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5042 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 |
| filingDate |
2007-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cd163f1716235b9fd4752560017bead
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_778e3f534499f83221fb1dd42137b13c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb2c7ee773ba75ba32ab5a03ba07b6ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2d8527e752416ebbc946912a06e3a08 |
| publicationDate |
2007-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2007173464-A1 |
| titleOfInvention |
Oral ribavirin pharmaceutical compositions |
| abstract |
The invention relates to oral pharmaceutical compositions for the prevention and/or the treatment of viral diseases. This invention also addresses methods of prevention and/or treatment of these viral diseases, using these oral compositions. One of the main problems considered in the present invention is to enhance the efficiency of anti-viral treatments, especially against Hepatitis C virus by means of ribavirin, for example in combination with interferon. The oral ribavirin antiviral composition according to the invention increases the bio-absorption time of ribavirin, and thus improves the treatment of patients. Said composition comprises at least one modified release form of ribavirin, the bio-absorption time BAT of which is greater than the bio-absorption time BAT* of a reference* immediate release form of ribavirin administered at the same dose; BAT being preferably comprised between 2 and 15 h and more preferably between 4 and 12 h. Said composition is a reservoir type form or a matrix type form. Said composition is a gastric retentive system or a multiparticulate form. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010132616-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006165807-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7910133-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8101209-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014130016-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006110463-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9814684-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7906145-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005037077-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10004693-B2 |
| priorityDate |
2005-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |